Annual hazard rates of recurrence for breast cancer after primary therapy - PubMed (original) (raw)
Multicenter Study
. 1996 Oct;14(10):2738-46.
doi: 10.1200/JCO.1996.14.10.2738.
Affiliations
- PMID: 8874335
- DOI: 10.1200/JCO.1996.14.10.2738
Multicenter Study
Annual hazard rates of recurrence for breast cancer after primary therapy
T Saphner et al. J Clin Oncol. 1996 Oct.
Abstract
Purpose: To determine if the long-term increase of recurrence for breast cancer is stable or slowly decreasing, or if it ever reaches zero; and to determine the effect of prognostic factors on the hazard of recurrence.
Methods: All patients entered onto the seven completed and unblinded Eastern Cooperative Oncology Group (ECOG) coordinated studies of postoperative adjuvant therapy for breast cancer were analyzed in terms of annual hazard of recurrence of breast cancer.
Results: For the entire group, the peak hazard of recurrence occurred in the interval of 1 to 2 years. The hazard decreased consistently in the interval of 2 to 5 years. Beyond 5 years, the hazard of recurrence decreased very, very slowly through year 12. The average hazard of recurrence between years 5 and 12 for the entire population was 4.3% per year. The pattern of a peak hazard of recurrence during the first 5 years with a slowly decreasing hazard of recurrence beyond 5 years was also observed to varying degrees in most subsets. Higher risk subsets such as patients with more than three nodes positive had a higher hazard of recurrence at all time intervals, while lower risk subsets such as patients with negative nodes had a lower hazard of recurrence in all time periods.
Conclusion: Patients 5 years postsurgery for breast cancer appear to have a very slowly decreasing hazard of recurrence. The mean hazard of recurrence between years 5 to 12 postsurgery is 4.3% per year. This group of patients may be well suited for trials evaluating cytostatic drugs or differentiating agents.
Similar articles
- Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
Chen X, Yu X, Chen J, Zhang Z, Tuan J, Shao Z, Guo X, Feng Y. Chen X, et al. Cancer. 2013 Jul 1;119(13):2366-74. doi: 10.1002/cncr.28085. Epub 2013 Apr 10. Cancer. 2013. PMID: 23576181 - Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
Fisher BJ, Perera FE, Cooke AL, Opeitum A, Stitt L. Fisher BJ, et al. Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):117-23. doi: 10.1016/s0360-3016(98)00177-1. Int J Radiat Oncol Biol Phys. 1998. PMID: 9747828 - Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Colleoni M, et al. J Clin Oncol. 2016 Mar 20;34(9):927-35. doi: 10.1200/JCO.2015.62.3504. Epub 2016 Jan 19. J Clin Oncol. 2016. PMID: 26786933 Free PMC article. - Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
Bogina G, Lunardi G, Coati F, Zamboni G, Gori S, Bortesi L, Marconi M, Cassandrini PA, Turazza M, Cortesi L, DeMatteis E, Ficarra G, Ibrahim T, Serra P, Medri L, Giraudi S, Lambertini M, Carli F, Foglietta J, Sidoni A, Nunzi M, Ficorella C, Diadema MR, Del Mastro L. Bogina G, et al. Tumori. 2015 Jul-Aug;101(4):398-403. doi: 10.5301/tj.5000323. Epub 2015 May 22. Tumori. 2015. PMID: 26045108 - Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. Woodward WA, et al. JAMA Oncol. 2020 Apr 1;6(4):505-511. doi: 10.1001/jamaoncol.2019.5559. JAMA Oncol. 2020. PMID: 31917424 Free PMC article. Clinical Trial.
Cited by
- Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.
Chumsri S, Pai T, Ma Y, Li Z, Gil A, Moreno-Aspitia A, Colon-Otero G, Pogue-Geile KL, Rasgoti P, Paik S, Perez EA, Thompson EA. Chumsri S, et al. J Natl Compr Canc Netw. 2024 Aug 26;22(7):463-468. doi: 10.6004/jnccn.2024.7015. J Natl Compr Canc Netw. 2024. PMID: 39191270 Free PMC article. Clinical Trial. - A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus.
Zhang R, Jiang Q, Zhuang Z, Zeng H, Li Y. Zhang R, et al. Front Immunol. 2024 Aug 12;15:1452303. doi: 10.3389/fimmu.2024.1452303. eCollection 2024. Front Immunol. 2024. PMID: 39188717 Free PMC article. - Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.
Richman J, Schuster G, Buus R, Lopez-Knowles E, Dowsett M. Richman J, et al. Breast Cancer Res Treat. 2024 Jul;206(1):195-205. doi: 10.1007/s10549-024-07311-z. Epub 2024 May 6. Breast Cancer Res Treat. 2024. PMID: 38709373 Free PMC article. - TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer.
Arimura A, Sakai K, Kaneshiro K, Morisaki T, Hayashi S, Mizoguchi K, Yamada M, Kai M, Ono M, Nishio K, Nakamura M, Kubo M. Arimura A, et al. Cancers (Basel). 2024 Mar 18;16(6):1184. doi: 10.3390/cancers16061184. Cancers (Basel). 2024. PMID: 38539518 Free PMC article. - Comparison of red and green light for treating non-muscle invasive bladder cancer in rats using singlet oxygen-cleavable prodrugs with PPIX-PDT.
Rahman KMM, Kumbham S, Bist G, Woo S, Foster BA, You Y. Rahman KMM, et al. Photochem Photobiol. 2024 Mar 27:10.1111/php.13933. doi: 10.1111/php.13933. Online ahead of print. Photochem Photobiol. 2024. PMID: 38533776
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical